UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________

Form 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September 30, 2021~~March 31, 2022

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________________ to _____________________

Commission File Number: 001-36426

____________

AquaBounty Technologies, Inc.

(Exact name of the registrant as specified in its charter)


Delaware	04-3156167
(State or other jurisdiction of ‎incorporation or organization)	(I.R.S. Employer ‎Identification No.)

2 Mill & Main Place, Suite 395

Maynard, Massachusetts 01754

(978) 648-6000

(Address and telephone number of the registrant’s principal executive offices)


Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common Stock, par value $0.001 per share	AQB	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or such shorter period that the registrant was required to submit such files).

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	o	Accelerated filer	o	Non-accelerated filer	x	Smaller reporting company	x
						Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

At ~~November 3, 2021,~~May 4, 2022, the registrant had ~~71,025,738~~71,109,701 shares of common stock, par value $0.001 per share (“Common Shares”) outstanding.

‎

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q, particularly the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward looking statements. All statements other than present and historical facts and conditions contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial positions, business strategy, plans, and our objectives for future operations, are forward-looking statements. When used in this Quarterly Report on Form 10-Q, the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions identify forward-looking statements. These forward-looking statements include statements that are not historical facts, including statements regarding management’s expectations for future financial and operational performance and operating expenditures, expected growth, and business outlook; the nature of and progress toward our commercialization plan; the future introduction of our products to consumers; the countries in which we may obtain regulatory approval and the progress toward such approvals; the volume of eggs or fish we may be able to produce; the timeline for our production of saleable fish; the expected advantages of land-based systems over sea cage production; the validity and impact of legal actions; the completion of renovations at our farms; and the establishment of a larger-scale grow-out facility.

We have based these forward-looking statements on our current expectations, assumptions, estimates, and projections. While we believe these expectations, assumptions, estimates, and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks, uncertainties, and other factors, many of which are outside of our control, which could cause our actual results, performance, or achievements to differ materially from any results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

the anticipated benefits and characteristics of AquaBounty’s genetically engineered AquAdvantage salmon (“~~GE”)~~GE Atlantic ~~salmon~~salmon”) product;

the implementation and likelihood of achieving the business plan, future revenue, and operating results;

our plans for (including without limitation, projected costs, locations and third-party involvement) and the timing of the development of new farms and the output of those ~~farms;~~farms (including our Pioneer, Ohio farm);

developments concerning our research projects;

our expectations regarding our ability to successfully enter new markets or develop additional products;

our competitive position and developments and projections relating to our competitors and our industry;

expectations regarding anticipated operating results;

our cash position and ability to raise additional capital to finance our activities;

the impact of the evolving COVID-19 pandemic (the “COVID-19 pandemic”) on our business, operations and financial results, any of which could be significantly impaired by the COVID-19 pandemic;

our ability to protect our intellectual property and other proprietary rights and technologies;

the impact of and our ability to adapt to changes in laws or regulations and policies;

the ability to secure any necessary regulatory approvals to commercialize any products;

the rate and degree of market acceptance of any products developed through the application of bioengineering, including genetically engineered fish;

our ability to retain and recruit key personnel;

the success of any of our future acquisitions or investments;

our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act (the “JOBS Act”);

our estimates regarding expenses, inflation, future revenue, capital requirements, and needs for additional financing; and

other risks and uncertainties referenced under “Risk Factors” below and in any documents incorporated by reference herein.

We caution you that the foregoing list may not contain all of the risks to which the forward-looking statements made in this Quarterly Report on Form 10-Q are subject. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included, particularly in the section titled “Risk Factors,” that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments that we may make.

Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this Quarterly Report on Form 10-Q. We do not undertake and specifically decline any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments unless required by federal securities law. New risks emerge from time to time, and it is not possible for us to predict all such risks.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

AquaBounty Technologies, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)


	As of
		September 30,	December 31,					March 31,			December 31,
		2021	2020				2022			2021
Assets
Current assets:
Cash and cash equivalents	$	118,179,653		$	95,751,160	$	75,509,793		$	88,454,988
Marketable securities		79,632,028			—		103,365,156			101,773,781
Inventory		1,222,223			1,525,377		1,675,682			1,259,910
Prepaid expenses and other current assets		1,197,830			405,370		1,695,159			1,536,484
Total current assets		200,231,734			97,681,907		182,245,790			193,025,163

Property, plant and equipment, net		30,008,937			26,930,338		37,828,165			33,815,119
Right of use assets, net		298,966			341,997		269,426			284,320
Intangible assets, net		235,268			245,546		228,417			231,842
Restricted cash		500,000			500,000		1,000,000			1,000,000
Other assets		78,204			76,715		75,957			79,548
Total assets	$	231,353,109		$	125,776,503	$	221,647,755		$	228,435,992

Liabilities and stockholders' equity
Current liabilities:
Accounts payable and accrued liabilities	$	1,953,716		$	1,760,103	$	2,913,028		$	4,317,615
Accrued employee compensation							512,173			874,589
Current debt							657,828			627,365
Other current liabilities		65,072			62,483		67,497			66,269
Current debt		619,552			259,939
Total current liabilities		2,638,340			2,082,525		4,150,526			5,885,838

Long-term lease obligations		241,102			290,327		206,734			224,058
Long-term debt, net		8,678,642			8,528,490		8,419,290			8,523,333
Total liabilities		11,558,084			10,901,342		12,776,550			14,633,229

Commitments and contingencies

Stockholders' equity:
Common stock, $0.001 par value, 80,000,000 shares authorized;
71,025,738 (2020: 55,497,133) shares outstanding		71,026			55,497
Common stock, $0.001 par value, 80,000,000 shares authorized at March 31, 2022 and
December 31, 2021; 71,109,701 and 71,025,738 shares outstanding at March 31, 2022
and December 31, 2021, respectively							71,110			71,026
Additional paid-in capital		384,763,523			263,629,116		385,063,351			384,852,107
Accumulated other comprehensive loss		(242,863)			(267,258)		(286,748)			(255,588)
Accumulated deficit		(164,796,661)			(148,542,194)		(175,976,508)			(170,864,782)
Total stockholders' equity		219,795,025			114,875,161		208,871,205			213,802,763

Total liabilities and stockholders' equity	$	231,353,109		$	125,776,503	$	221,647,755		$	228,435,992

See accompanying notes to these condensed interim consolidated financial statements.

AquaBounty Technologies, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended ‎March 31,
	2021		2020		2021		2020		2022		2021
Revenues
Product revenues	$	455,397	$	67,763	$	757,162	$	77,466	$	962,881	$	74,372

Costs and expenses
Product costs		4,311,003		1,355,939		7,713,254		3,238,689		3,275,690		1,554,655
Sales and marketing		201,838		143,646		1,069,354		331,868		247,572		318,635
Research and development		580,346		458,462		1,512,339		1,662,879		167,189		500,620
General and administrative		2,177,153		1,722,874		6,541,621		5,053,608		2,376,236		1,785,510
Total costs and expenses		7,270,340		3,680,921		16,836,568		10,287,044		6,066,687		4,159,420

Operating loss		(6,814,943)		(3,613,158)		(16,079,406)		(10,209,578)		(5,103,806)		(4,085,048)

Other income (expense)
Interest expense		(79,489)		(38,335)		(238,503)		(73,527)		(75,288)		(78,804)
Other income (expense), net		29,593		1,705		63,442		15
Other income, net										67,368		4,961
Total other income (expense)		(49,896)		(36,630)		(175,061)		(73,512)		(7,920)		(73,843)

Net loss	$	(6,864,839)	$	(3,649,788)	$	(16,254,467)	$	(10,283,090)	$	(5,111,726)	$	(4,158,891)

Other comprehensive income (loss):
Foreign currency		(136,670)		86,491		9,293		(129,993)
Unrealized gains		6,132		—		15,102		—
Foreign currency translation gain										82,905		80,039
Unrealized loss on marketable securities										(114,065)		—
Total other comprehensive income (loss)		(130,538)		86,491		24,395		(129,993)		(31,160)		80,039

Comprehensive loss	$	(6,995,377)	$	(3,563,297)	$	(16,230,072)	$	(10,413,083)	$	(5,142,886)	$	(4,078,852)


Basic and diluted net loss per share	$	(0.10)	$	(0.09)	$	(0.24)	$	(0.31)	$	(0.07)	$	(0.06)
Weighted average number of common shares -
Weighted average number of Common Shares -
basic and diluted		71,025,738		38,911,054		68,889,650		32,756,074		71,004,454		64,550,920

See accompanying notes to these condensed interim consolidated financial statements.

AquaBounty Technologies, Inc.

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)

Common stock issued and outstanding
Par value
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total
Balance at December 31, 2019
21,635,365
$
21,635
$
156,241,363
$
(360,160)
$
(132,142,209)
$
23,760,629
Net loss
(3,109,618)
(3,109,618)
Other comprehensive income (loss)
(381,985)
(381,985)
Issuance of common stock, net of expenses
10,350,000
10,350
14,511,354
14,521,704
Share based compensation
100,319
101
205,252
205,353
Balance at March 31, 2020
32,085,684
32,086
170,957,969
(742,145)
(135,251,827)
34,996,083
Net loss
(3,523,684)
(3,523,684)
Other comprehensive income (loss)
165,501
165,501
Issuance of common stock, net of expenses
20,000
20
40,580
40,600
Share based compensation
103,891
103,891
Balance at June 30, 2020
32,105,684
32,106
171,102,440
(576,644)
(138,775,511)
31,782,391
Net loss
(3,649,788)
(3,649,788)
Other comprehensive income (loss)
86,491
86,491
Issuance of common stock, net of expenses
12,650,000
12,650
29,701,947
29,714,597
Exercise of warrants for common stock
161,242
161
523,876
524,037
Share based compensation
74,720
74,720
Balance at September 30, 2020
44,916,926
$
44,917
$
201,402,983
$
(490,153)
$
(142,425,299)
$
58,532,448

‎



	Common stock issued and outstanding		Par value		Additional paid-in capital		Accumulated other comprehensive loss		Accumulated deficit		Total		Common stock issued and outstanding		Par value		Additional paid-in capital		Accumulated other comprehensive loss		Accumulated deficit		Total
Balance at December 31, 2020		55,497,133	$	55,497	$	263,629,116	$	(267,258)	$	(148,542,194)	$	114,875,161		55,497,133	$	55,497	$	263,629,116	$	(267,258)	$	(148,542,194)	$	114,875,161
Net loss										(4,158,891)		(4,158,891)										(4,158,891)		(4,158,891)
Other comprehensive income (loss)								80,039				80,039								80,039				80,039
Cashless exercise of options for common stock		4,354		4		(4)						—		4,354		4		(4)						—
Issuance of common stock, net of expenses		14,950,000		14,950		119,105,487						119,120,437		14,950,000		14,950		119,105,487						119,120,437
Exercise of warrants for common stock		491,133		491		1,595,691						1,596,182		491,133		491		1,595,691						1,596,182
Share based compensation		40,525		41		129,674						129,715		40,525		41		129,674						129,715
Balance at March 31, 2021		70,983,145		70,983		384,459,964		(187,219)		(152,701,085)		231,642,643		70,983,145	$	70,983	$	384,459,964	$	(187,219)	$	(152,701,085)	$	231,642,643
Net loss										(5,230,737)		(5,230,737)
Other comprehensive income (loss)								74,894				74,894
Exercise of warrants for common stock		39,281		39		127,625						127,664
Share based compensation		3,312		4		87,350						87,354
Balance at June 30, 2021		71,025,738		71,026		384,674,939		(112,325)		(157,931,822)		226,701,818

													Common stock issued and outstanding		Par value		Additional paid-in capital		Accumulated other comprehensive loss		Accumulated deficit		Total
Balance at December 31, 2021														71,025,738	$	71,026	$	384,852,107	$	(255,588)	$	(170,864,782)	$	213,802,763
Net loss										(6,864,839)		(6,864,839)										(5,111,726)		(5,111,726)
Other comprehensive income (loss)								(130,538)				(130,538)								(31,160)				(31,160)
Share based compensation						88,584						88,584		83,963		84		211,244						211,328
Balance at September 30, 2021		71,025,738	$	71,026	$	384,763,523	$	(242,863)	$	(164,796,661)	$	219,795,025
Balance at March 31, 2022														71,109,701	$	71,110	$	385,063,351	$	(286,748)	$	(175,976,508)	$	208,871,205

See accompanying notes to these condensed interim consolidated financial statements.

AquaBounty Technologies, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Nine Months Ended September 30,				Three Months Ended March 31,
	2021		2020		2022		2021
Operating activities
Net loss	$	(16,254,467)	$	(10,283,090)	$	(5,111,726)	$	(4,158,891)
Adjustment to reconcile net loss to net cash used in
operating activities:
Depreciation and amortization		1,308,062		1,082,261		490,563		422,185
Share-based compensation		305,653		383,964		211,328		129,715
Other non-cash charge		12,993		40,151		4,251		4,203
Changes in operating assets and liabilities:
Inventory		303,767		(1,638,981)		(411,794)		(577,154)
Prepaid expenses and other assets		(794,573)		(536,165)		(139,671)		(63,966)
Accounts payable and accrued liabilities		7,273		366,403		(6,949)		(211,347)
Accrued employee compensation						(362,416)		(63,139)
Net cash used in operating activities		(15,111,292)		(10,585,457)		(5,326,414)		(4,518,394)

Investing activities
Purchase of property, plant and equipment		(4,160,370)		(2,640,039)
Proceeds from sale of asset held for sale		—		99,816
Purchases and deposits on property, plant and equipment						(5,762,143)		(1,208,183)
Purchases of marketable securities, net		(79,647,130)		—		(1,705,440)		—
Proceeds from legal settlement, net		—		1,014,008
Other investing activities		(11,010)		(18,900)		—		(11,010)
Net cash used in investing activities		(83,818,510)		(1,545,115)		(7,467,583)		(1,219,193)

Financing activities
Proceeds from issuance of debt		606,453		4,129,510		—		187,120
Repayment of term debt		(119,527)		(49,862)		(159,304)		(38,885)
Proceeds from the issuance of common stock, net		119,120,437		44,236,301		—		119,120,437
Proceeds from the exercise of stock options and warrants		1,723,846		524,037		—		1,596,182
Net cash provided by financing activities		121,331,209		48,839,986
Net cash (used in) provided by financing activities						(159,304)		120,864,854

Effect of exchange rate changes on cash, cash equivalents and restricted cash		27,086		(18,792)		8,106		21,007
Net change in cash, cash equivalents and restricted cash		22,428,493		36,690,622		(12,945,195)		115,148,274
Cash, cash equivalents and restricted cash at beginning of period		96,251,160		2,798,744		89,454,988		96,251,160
Cash, cash equivalents and restricted cash at end of period	$	118,679,653	$	39,489,366	$	76,509,793	$	211,399,434

Reconciliation of cash, cash equivalents and restricted cash reported
in the consolidated balance sheet:
Cash and cash equivalents	$	118,179,653	$	39,489,366	$	75,509,793	$	210,899,434
Restricted cash		500,000		—		1,000,000		500,000
Total cash, cash equivalents and restricted cash	$	118,679,653	$	39,489,366	$	76,509,793	$	211,399,434

Supplemental disclosure of cash flow information and
non-cash transactions:
Interest paid in cash	$	224,595	$	47,275	$	71,037	$	73,685
Property and equipment included in accounts payable and accrued liabilities	$	206,423	$	517,344	$	1,507,514	$	82,068

See accompanying notes to these condensed interim consolidated financial statements.

AquaBounty Technologies, Inc.

Notes to the condensed consolidated financial statements

(unaudited)

1. Nature of business and organization

AquaBounty Technologies, Inc. (the “Parent” and, together with its wholly owned subsidiaries, the “Company”) was incorporated in December 1991 in the State of Delaware for the purpose of conducting research and development of the commercial viability of a group of proteins commonly known as antifreeze proteins. In 1996, the Parent obtained the exclusive licensing rights for a gene construct (transgene) used to create a breed of ~~farm-raised~~farm-raised Atlantic salmon that exhibit growth rates that are substantially faster than conventional salmon. In 2015, the Parent obtained regulatory approval from the USU.S. Food and Drug Administration ~~(the “FDA”~~(“FDA”) for the production and sale of its GE Atlantic salmon in the United States and in 2016, the Parent obtained regulatory approval from Health Canada for the production and sale of its GE Atlantic salmon in Canada. In 2021, the Parent obtained regulatory approval from ~~Brazil’s~~the National Biosafety Technical Commission for the sale of its GE Atlantic salmon in Brazil.

~~AquaBounty Farms, Inc. (the “U.S. Subsidiary”) was incorporated in December 2014 in~~ In 2021, the ~~State of Delaware for the purpose of conducting field trials~~Company began harvesting and ~~commercializing the Parent’s products~~selling its GE Atlantic salmon in the United ~~States. During June 2021, the Company established AquaBounty Farms Ohio LLC (the “Ohio Subsidiary”), a wholly owned entity of the U.S. Subsidiary.~~States and Canada.

2. Basis of presentation

The unaudited interim condensed consolidated financial statements include the accounts of AquaBounty Technologies, Inc. and its wholly owned direct subsidiaries, AQUA Bounty Canada Inc.; AquaBounty Farms, Inc.; AquaBounty Panama, S. de R.L.; and AquaBounty Brasil Participações Ltda. The entities are collectively referred to herein as the “Company.”subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.

The unaudited interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited financial statements and related notes for the year ended December 31, ~~2020.~~2021. The unaudited interim condensed consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the Company’s financial position as of ~~September 30, 2021~~March 31, 2022, results of operations and cash flows for the interim periods presented, and are not necessarily indicative of results for subsequent interim periods or for the full year. The unaudited interim condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements, as allowed by the relevant U.S. Securities and Exchange Commission (“SEC”) rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading.

Liquidity

~~In February 2021, the~~The Company ~~completed an equity raise with net proceeds of $119.1 million and has $198~~had $179.9 million in cash and cash equivalents, ~~and~~ marketable securities and restricted cash as of ~~September 30, 2021.~~March 31, 2022. While the Company has experienced net losses and negative cash flows from operations since inception, management believes that it has sufficient cash to meet the Company's requirements beyond the next twelve months from the filing date of these condensed consolidated financial statements. However, until such time as the Company reaches profitability, it may require additional financing to fund its operations and execute its business plan.

Inventories

Inventories are mainly comprised of feed, eggs, ~~and~~ fish in ~~process.~~process and finished goods. Fish in process inventory is measured based on the estimated biomass of fish on hand. The Company has established a standard procedure to estimate the biomass of fish on hand using counting and sampling techniques. The Company measures inventory at the lower of cost or net realizable value (NRV). The NRV calculation contains various estimates and assumptions in regard to the calculation of the biomass, including expected yield, the market value of the biomass and estimated costs of completion and transportation. The Company considers fish that has been harvested and transported from its farm to be finished goods inventory.

Revenue recognition

The Company ~~records~~generates revenue onfrom the sale of ~~a product~~its products. Revenue is recognized when ~~all revenue recognition criteria are fulfilled, including identifying~~ the ~~contract with a customer; identifying~~customer takes physical control of the ~~performance obligations~~goods, in ~~the contract; determining the transaction price; allocating~~an amount that reflects the transaction price ~~to the performance obligations in the contract; and recognizing revenue when (or as)~~consideration that the Company ~~satisfies a performance obligation. The Company evaluates customer credit risk in order~~expects to ~~conclude it is “probable” it will collect the amount of consideration due~~receive in exchange for the ~~goods or services.~~goods. Revenue excludes any sales tax collected and includes any estimate of future credits.

During the period ended March 31, 2022, the Company recognized the following product revenue:


	Quarter Ended March 31, 2022
		U.S.		Canada		Total
GE Atlantic salmon	$	788,977	$	131,860	$	920,837
Non-GE Atlantic salmon fry		-		41,807		41,807
Other revenue		-		237		237
Total Revenue	$	788,977	$	173,904	$	962,881

During the period ended March 31, 2022, the Company had the following customer concentration of revenue:


	Quarter Ended
	March 31, 2022
Customer A		34%
Customer B		21%
Customer C		14%
All other		31%
Total of all customers		100%

Net loss per share

Basic and diluted net loss per share available to common stockholders has been calculated by dividing net loss by the weighted average number of ~~common shares~~Common Shares outstanding during the year. Basic net loss per share is based solely on the number of ~~common shares~~Common Shares outstanding during the year. Common Shares outstanding exclude any issued, but unvested restricted shares. Fully diluted net loss per share includes the number of ~~shares of common stock~~Common Shares issuable upon the exercise of warrants and options with an exercise price less than the fair value of the ~~common stock unless the impact of the warrant or option is anti-dilutive to the calculation.~~Common Shares, as well as all issued but unvested restricted shares. Since the Company is reporting a net loss for all periods presented, all potential ~~common shares~~Common Shares are considered ~~anti~~-~~dilutive~~anti-dilutive and are excluded from the calculation of diluted net loss per share.

~~At September 30, 2021,~~

The following table shows the ~~Company had 1,081,866~~impact of potentially dilutive securities ~~outstanding, consisting of 418,441 warrants and 663,425 stock options.~~outstanding:


	March 31, 2022	December 31, 2021
Shares issued and outstanding, excluding unvested restricted shares	71,087,504	70,992,361
Reserve for issued stock options	873,180	663,425
Reserve for issued warrants	418,441	418,441
Reserve for issued but unvested restricted shares	184,645	65,100
Fully diluted shares	72,563,770	72,139,327

Accounting Pronouncements

Management does not expect any recently issued, but not yet effective, accounting standards to have a material effect on its results of operations or financial condition.

3. Risks and uncertainties

The Company is subject to risks and uncertainties common in the biotechnology and aquaculture industries. Such risks and uncertainties include, but are not limited to: (i) results from current and planned product development studies and trials; (ii) decisions made by the FDA or similar regulatory bodies in other countries with respect to approval and commercial sale of any of the Company’s proposed products; (iii) the commercial acceptance of any products approved for sale and the Company’s ability to produce, distribute, and sell for a profit any products approved for sale; (iv) the Company’s ability to obtain the necessary patents and proprietary rights to effectively protect its technologies; and (v) the outcome of any collaborations or alliances entered into by the Company.

COVID-19

Although the COVID-19 pandemic has diminished in the United States and other parts of the world as vaccines have become more readily available, several variants of the virus continue to spread. Local governmental authorities in the United States and Canada have issued, and continue to update, directives aimed at minimizing the spread of the virus and the Company continues to monitor its status.

The ultimate impact of the evolving COVID-19 pandemic on the Company’s operations will depend on future developments, which cannot be predicted with confidence, and the Company cannot predict the extent or impact of the extended period of continued business interruption and reduced operations caused by the COVID-19 pandemic or any additional preventative or protective measures taken in response. In connection with the COVID-19 pandemic, management made modifications to biosecurity procedures at the farm sites in early 2020 to adapt to local requirements and to provide a safe work environment. The Company’s current preventative and protective measures include, but are not limited to, segregating farm workers to specific locations, rotating shifts, and monitoring worker temperatures upon arrival at the Company’s facilities. To the extent possible, work-from-home is utilized for employees that do not have fish care responsibilities.

Due to the pandemic, the Company has experienced delays and cost increases in capital projects, additional challenges in its efforts to meet the capacity expectations at existing facilities and continues to experience extended lead times on equipment purchases. The Company may continue to experience delays and cost increases on farm construction, purchases of capital equipment and supplies and other materials required in its operations due to vendor shortages and labor shortages. The Company also expects to continue to be impacted by transportation or other supply chain disruptions to its partners or customers. In addition, the Company is carefully managing and monitoring the impact of labor shortages on its ability to meet the annual capacity expectations at its existing facilities.

The Company was initially impacted by a reduction in the market price and demand for Atlantic salmon due to the pandemic’s impact on the food service sector. This had a negative impact on revenue and inventory value, as the Company was not yet an established vendor and customers were reluctant to add a new supplier during a period of depressed demand.

During the third quarter, the Company was impacted by a shortage of labor at its Indiana farm and increased costs for third-party processing and transportation. This had a negative effect on revenue and inventory values and resulted in higher than expected sales costs for the period. This is expected to continue for the foreseeable future.

The Company remains focused on maintaining a strong balance sheet, liquidity, and financial flexibility and continues to monitor developments as it deals with the disruptions and uncertainties from a business and financial perspective related to the evolving COVID-19 pandemic.

taken in response. In connection with the COVID-19 pandemic, management continues to make modifications to biosecurity procedures and employee welfare practices at the Company’s farm sites to adapt to local requirements and to provide a safe work environment.

Concentration of credit risk

Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and marketable ~~securities and debt.~~securities. This risk is mitigated by the Company’s policy of maintaining all balances with highly rated financial institutions, investing cash equivalents with maturities of less than 90 days, and investing marketable securities with maturities of less than 180 days. The Company’s cash balances may at times exceed insurance limitations. The Company holds cash balances in bank accounts located in Canada to fund its local operations. These amounts are subject to foreign currency exchange risk, which is minimized by the Company’s policy to limit the balances held in these accounts. Balances in Canadian bank accounts totaled ~~$229~~$147 thousand and $224 thousand at ~~September 30, 2021.~~March 31, 2022 and December 31, 2021, respectively. The Company also holds cash equivalent investments in a highly liquid investment account at a major financial institution. ~~At September 30,~~As of March 31, 2022 and December 31, 2021 the cash equivalent investment balance was ~~$100.4 million. All of the Company’s interest-bearing debt is at fixed rates, except for the loan with First Farmer’s Bank~~$56.7 million and ~~Trust, which has a rate reset in July 2025.~~$73.3 million, respectively.

4. Marketable Securities

Marketable securities are classified as available-for-sale. The following ~~table summarizes~~tables summarize the amortized cost, gross unrealized gains and losses, and the fair value as of ~~September 30,~~March 31, 2022 and December 31, 2021:


		Amortized		Unrealized		Unrealized		Market		Amortized		Unrealized		Unrealized		Market
		Cost		Gains		Losses		Value		Cost		Gains		Losses		Value
	September 30, 2021								December 31, 2021
Government bonds	$	42,298,225	$	140	$	(9,554)	$	42,288,811	$	28,453,161	$	82	$	(18,255)	$	28,434,988
Corporate bonds		22,350,050		7,620		(12,967)		22,344,703		29,874,696		-		(21,928)		29,852,768
Commercial paper		14,998,514		-		-		14,998,514		43,486,025		-		-		43,486,025
Marketable securities	$	79,646,789	$	7,760	$	(22,521)	$	79,632,028	$	101,813,882	$	82	$	(40,183)	$	101,773,781

									March 31, 2022
Government bonds									$	37,488,888	$	33	$	(86,090)	$	37,402,831
Corporate bonds										26,549,151		15		(68,035)		26,481,132
Commercial paper										39,481,194		-		-		39,481,194
Marketable securities									$	103,519,232	$	48	$	(154,125)	$	103,365,156

Major classifications of property, plant and equipment are summarized as follows:

7.~~Accounts payable and accrued liabilities~~

~~Accounts payable and accrued liabilities include the following:~~

September 30, 2021
December 31, 2020
Accounts payable
$
860,673
$
799,888
Accrued payroll including vacation
577,534
583,301
Accrued professional fees and contract services
394,433
278,165
Accrued taxes and other
121,076
98,749
Accounts payable and accrued liabilities
$
1,953,716
$
1,760,103

8. Debt

The current material terms and conditions of debt outstanding are as follows:


	Interest ‎rate	Monthly ‎repayment	Maturity ‎date	September 30, 2021		December 31, 2020		Interest ‎rate	Monthly ‎repayment	Maturity ‎date	March 31, 2022		December 31, 2021
ACOA AIF Grant	0%	Royalties	-	$	2,259,339	$	2,253,595	0%	Royalties	-	$	2,296,099	$	2,261,349
ACOA term loan #1	0%	C$3,120	Feb 2027		159,574		181,203	0%	C$3,120	Feb 2027		147,204		152,346
ACOA term loan #2	0%	C$4,630	Sep 2029		349,641		381,451	0%	C$4,630	Sep 2029		333,120		339,015
ACOA term loan #3	0%	C$6,945	Dec 2025		196,675		—	0%	C$6,945	Dec 2025		199,875		196,850
Kubota Canada Ltd	0%	C$1,142	Jan 2025		35,949		43,925	0%	C$1,142	Jan 2025		31,054		33,283
DFO term loan								0%	C$2,091	Aug 2032		411,935		405,700
PEI Finance term loan	4%	C$16,313	Nov 2023		1,964,748		2,014,321	4%	C$16,313	Nov 2023		1,957,755		1,947,510
DFO term loan	0%	C$2,091	Aug 2032		405,340		—
First Farmers Bank & Trust term loan	5.375%	$56,832	Oct 2028		4,000,000		4,000,000	5.375%	$56,832	Oct 2028		3,764,506		3,883,325
Total debt				$	9,371,266	$	8,874,495				$	9,141,548	$	9,219,378
less: debt issuance costs					(73,072)		(86,066)					(64,430)		(68,680)
less: current portion					(619,552)		(259,939)					(657,828)		(627,365)
Long-term debt, net				$	8,678,642	$	8,528,490				$	8,419,290	$	8,523,333


	AIF		ACOA		FPEI		Kubota			DFO	FFBT		Total		Total
2021	$	—	$	18,291	$	18,969	$	2,696	$	—	$	116,676	$	156,632
2022		—		73,163		77,582		10,785		—		482,306		643,836
2022 (remainder of the year)															$	486,634
2023		—		138,727		1,868,197		10,785		35,555		509,256		2,562,520		2,595,928
2024		—		138,727		—		10,785		42,667		537,276		729,455		732,581
2025		—		138,711		—		898		42,668		567,735		750,012		752,978
2026																717,174
Thereafter		2,259,339		198,271		—		—		284,450		1,786,751		4,528,811		3,856,253
Total	$	2,259,339	$	705,890	$	1,964,748	$	35,949	$	405,340	$	4,000,000	$	9,371,266	$	9,141,548

In September 2020, the Canadian Subsidiary entered into a Contribution Agreement with ~~DFO's~~the Department of Fisheries and Ocean's Atlantic Fisheries Fund, whereby it is eligible to receive up to C$1.9 million ($1.4 million) to finance new equipment for its Rollo Bay farm (the “DFO Term Loan”). On ~~February 25, 2021,~~April 6, 2022, the Canadian Subsidiary borrowed an additional C$~~238,400~~53,456 ($~~187,120) and on April 27, 2021 the Canadian Subsidiary borrowed C$276,840 ($219,258)~~42,241) under the DFO Term Loan. Borrowings are interest free and monthly repayments commence in March 2023, with maturity in August 2032. All funding requests must be submitted by August 22, 2022.

~~On July 8, 2021,~~In August 2020, the ~~Canadian~~Indiana Subsidiary entered into a ~~contribution~~term loan agreement with First Farmers Bank and Trust (“FFBT”) in the ~~Atlantic Canada Opportunities Agency under~~amount of $4 million, which is secured by the assets of the Indiana subsidiary and a corporate guarantee. The agreement contains certain financial and non-financial covenants, which if not met, could result in an event of default pursuant to the terms of the loan. At March 31, 2022, the Indiana subsidiary was in non-compliance with one of its ~~REGI-Business Scale-up~~loan covenants. Subsequent to period-end, FFBT revised the covenant and ~~Productivity program that can provide up~~the Indiana subsidiary returned to ~~C$250 thousand ($200 thousand) in funding assistance.~~ ~~On August 20, 2021, the Canadian Subsidiary received C$250,000 ($200,075).~~ ~~All funds received are to be repaid over a 36-month term commencing January 2023 at a 0% interest rate.~~compliance.

The Company recognized interest expense of ~~$238~~$75 thousand and ~~$73~~$79 thousand for the ~~nine~~three months ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020,~~ respectively, on its interest-bearing debt.

The table below summarizes the Company’s lease obligations and remaining payments at ~~September 30,~~March 31, 2022 and December 31, 2021:

September 30, 2021
December 31, 2020
Lease
Lease
Remaining
Remaining
Lease
Remaining
Lease
Type
Term
Years
Payments
Liability
Payments
Liability
Maynard Office Lease
Operating
Mar 2023
1.4
101,403
92,114
150,918
134,099
Indiana Auto Lease
Operating
Feb 2021
-
-
1,157
821
Indiana Well Lease
Operating
Dec 2048
27.2
674,810
214,060
686,809
217,890
Total
776,213
306,174
838,884
352,810
Less: current portion
(83,960)
(65,072)
(83,571)
(62,483)
Long-term leases
$ 692,253
$ 241,102
$ 755,313
$ 290,327



	March 31, 2022		December 31, 2021
		Lease Liability		Lease Liability
Total leases	$	274,231	$	290,327
Less: current portion		(67,497)		(66,269)
Long-term leases	$	206,734	$	$ 224,058

Remaining payments under leases are as ~~follows at September 30, 2021:~~follows:


Year	Office	Well	Amount			Amount
2021	16,901	4,000	20,901
2022	67,602	16,478	84,080
2022 (remainder of the year)				2022 (remainder of the year)	$	50,173
2023	16,900	16,972	33,872			20,831
2024	-	17,481	17,481			4,495
2025	-	18,006	18,006			4,340
2026						4,215
Thereafter	-	601,873	601,873			190,177
Total Lease Payments	101,403	674,810	776,213
Total lease payments					$	274,231

On February 8, 2021, the Company completed a public offering of 14,950,000 Common Shares for net proceeds of approximately $119.1 million.

~~The following table summarizes information about~~At March 31, 2022 and December 31, 2021, there were 418,441 warrants outstanding ~~warrants~~ at ~~September 30, 2021,~~an exercise price of $3.25, all of which were issued in conjunction with a public equity offering in January ~~2018:~~

At ~~September 30, 2021,~~March 31, 2022, the Company has reserved ~~663,425~~873,180 Common Shares issuable upon the exercise of outstanding stock options awarded under its 2006 and 2016 Equity Incentive Plans. An additional ~~916,516~~465,984 Common Shares are reserved for future award and issuance under the 2016 Equity Incentive Plan.

During the three months ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020,~~ the Company expensed ~~$194~~$168 thousand and ~~$160~~$107 thousand, respectively related to the restricted stock awards. At ~~September 30, 2021,~~March 31, 2022, the balance of unearned share-based compensation to be expensed in future periods related to the restricted stock awards is ~~$193~~$347 thousand. The period over which the unearned share-based compensation is expected to be earned is approximately ~~2.5~~2 years.

Stock options

The Company’s option activity is summarized as follows:

Number of
‎options
Weighted
‎average
‎exercise price
Outstanding at December 31, 2020
657,414
$
4.28
Granted
48,914
6.72
Exercised
(16,667)
6.90
Forfeited
(1,959)
6.72
Expired
(24,277)
6.39
Outstanding at September 30, 2021
663,425
$
4.31
Exercisable at September 30, 2021
594,458
$
4.33


	Number of ‎options	Weighted ‎average ‎exercise price
Outstanding at December 31, 2021	663,425	$	4.31
Issued	209,755		1.55
Exercised	—		—
Forfeited	—		—
Expired	—		—
Outstanding at March 31, 2022	873,180	$	3.65
Exercisable at March 31, 2022	624,075	$	4.31

Unless otherwise indicated, options issued to employees, members of the Board of Directors, and non-employees are vested daily over one to three years and are exercisable for a term of ten years from the date of issuance.

The fair values of stock option grants to employees and members of the Board of Directors during ~~2021~~2022 were measured on the date of grant using Black-Scholes, with the following weighted average assumptions:


		~~March 2021~~2022
Expected volatility		~~111%~~103%
Risk free interest rate		~~0.80%~~2.10%
Expected dividend yield		0%
Expected life (in years)		5

The weighted average fair value of stock options granted during the three ~~and nine~~ months ended ~~September 30, 2021,~~March 31, 2022 was ~~$5.36.~~$1.12.

The total intrinsic value of all options outstanding was ~~$958~~$73 thousand and ~~$3.6 million~~$18 thousand at ~~September 30, 2021,~~March 31, 2022, and December 31, ~~2020,~~2021, respectively. The total intrinsic value of exercisable options was ~~$878~~$1 thousand and ~~$3.2 million~~$11 thousand at ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, respectively.

‎

The following table summarizes information about options outstanding and exercisable at ~~September 30, 2021:~~March 31, 2022:


Weighted ‎average exercise ‎price of outstanding ‎options	Number of ‎options ‎outstanding	Weighted ‎average remaining ‎estimated life ‎(in years)	Number of ‎options ‎exercisable	Number of ‎options ‎outstanding	Weighted ‎average remaining ‎estimated life ‎(in years)	Number of ‎options ‎exercisable
$1.88 - $2.50	524,019	7.5	487,390
$3.30 - $6.72	53,916	8.6	21,578
$1.52 - $2.50				732,288	7.9	503,779
$5.44 - $6.72				55,402	8.2	34,789
$7.50 - $10.80	16,403	2.6	16,403	16,403	2.1	16,403
$14.20 - $23.40	69,087	4.5	69,087	69,087	4.0	69,087
	663,425		594,458	873,180		624,058

Total share-based compensation on stock options amounted to ~~$111~~$43 thousand and ~~$224~~$22 thousand for the three months ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020,~~ respectively. At ~~September 30, 2021,~~March 31, 2022, the balance of unearned share-based compensation to be expensed in future periods related to unvested share-based awards was ~~$225~~$374 thousand. The period over which the unearned share-based compensation is expected to be earned is approximately ~~2.5~~2 years.

The Company recognizes and discloses commitments when it enters into executed contractual obligations with other parties. The Company accrues contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.

The Company is subject to legal proceedings and claims arising in the normal course of business. The Company records estimated losses from these legal proceedings and claims when it determines that it is probable a liability has been incurred and the amount of loss can be reasonably estimated. Litigation is subject to many factors that are difficult to predict so that there can be no assurance, in the event of a material unfavorable result in one or more claims, the Company will not incur material costs. There have been no other material changes to the commitments and contingencies disclosed in the Company’s Annual Report on Form 10-K as of and for the year ended December 31, ~~2020.~~2021.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021, which was filed on March ~~9, 2021.~~10, 2022.

Overview

We believe ~~that~~ we are a leader in ~~the field of~~ land-based aquaculture, ~~and the use~~leveraging decades of technology ~~for~~expertise to deliver innovative solutions that address food insecurity and climate change issues, while improving ~~its productivity~~efficiency, sustainability and ~~sustainability.~~profitability. We provide fresh Atlantic salmon to nearby markets by raising our fish in carefully monitored land-based fish farms through a safe, secure and sustainable process. Our land-based Recirculating Aquaculture System farms, located in Indiana, United States and Prince Edward Island, Canada, are close to key consumption markets and are designed to prevent disease and to include multiple levels of fish containment to protect wild fish populations. We are raising nutritious salmon that is free of antibiotics and other contaminants and provides a solution with a reduced carbon footprint and no risk of pollution to marine ecosystems as compared to traditional sea-cage farming. Our lead product is our GE Atlantic salmon, which received FDA approval in 2015 as the first genetically engineered animal available for sale for human consumption. We ~~have~~ commenced commercial activities in 2021 with operations in the United States and Canada where we have received regulatory approval. We are actively engaged in genetic, genomic, fish health and fish nutrition research, which drive continuous improvement in our operations and may lead to new, disruptive technologies and products that could further expand our competitive offerings.

COVID-19

The ultimate impact of the evolving COVID-19 pandemic on our operations will depend on future developments, which cannot be predicted with confidence, and we cannot predict the extent or impact of the extended period of continued business interruption and reduced operations caused by the COVID-19 pandemic or any additional preventative or protective measures taken in response. In connection with the COVID-19 pandemic, we ~~made~~continue to make modifications to our biosecurity procedures and our employee welfare practices at ~~the~~our farm sites ~~in early 2020~~ to adapt to local requirements and to provide a safe work environment. Our current preventative and protective measures include, but are not limited to, segregating farm workers to specific locations, rotating shifts, and monitoring worker temperatures upon arrival at our facilities. To the extent possible, work-from-home is utilized for employees that do not have fish care responsibilities.

Due to the pandemic, we have experienced delays and cost increases in capital projects, additional challenges in our efforts to meet the capacity expectations at our existing facilities and continue to experience extended lead times on equipment purchases. We may continue to experience delays and cost increases on farm construction, purchases of capital equipment and supplies and other materials required in our operations due to vendor shortages and other labor shortages. We also expect to continue to be impacted by transportation or supply chain disruptions to our partners or customers. In addition, we are carefully managing and monitoring the impact of labor shortages on our ability to meet the annual capacity expectations at our existing facilities.

Our operations were initially impacted by a reduction in the market price and demand for Atlantic salmon due to the pandemic’s impact on the food service sector. This had a negative impact on revenue and inventory value, as we were not yet an established vendor and customers were reluctant to add a new supplier during a period of depressed demand.

During the third quarter, we were impacted by a shortage of labor at our Indiana farm and increased costs for third-party processing and transportation. This had a negative effect on revenue and inventory values and resulted in higher than expected sales costs for the period. We expect this to continue for the foreseeable future.

We remain focused on maintaining a strong balance sheet, liquidity, and financial flexibility and continue to monitor developments as we deal with the disruptions and uncertainties from a business and financial perspective relating to the evolving COVID-19 pandemic.

Revenue

We currently generate product revenue through the sales of our GE Atlantic salmon, conventional Atlantic salmon eggs and fry, and salmon byproducts. We expect revenues ~~for the remainder of 2021~~ to ~~slowly~~ grow modestly in 2022, as we increase our weekly harvesting capability at our Indiana ~~and Rollo Bay farm sites.~~farm. In the future, we believe that our revenue will depend upon the number and capacity of grow-out farms we have in operation and the market acceptance we achieve.

Production Costs

Production costs include the labor and related costs to grow out our fish, including feed, oxygen, and other direct costs; overhead; and the cost to process and ship our products to customers. A portion of production costs ~~are~~is absorbed into inventory as fish in process to the extent that these costs do not exceed the net realizable value of the fish biomass. The costs that are not absorbed into inventory, as well as any net realizable inventory value adjustments, are classified as production costs. As of ~~September 30,~~March 31, 2022 and 2021, we had ~~sixty-one~~sixty-four and forty-three employees, respectively engaged in production activities.

Research and Development Expenses

As of ~~September 30,~~March 31, 2022 and 2021, we employed ~~twenty~~twenty-two and fifteen scientists and technicians, respectively at our facilities on Prince Edward Island to oversee our broodstock of GE Atlantic salmon, as well as the lines of fish we maintain for research and development purposes. We recognize research and development expenses as they are incurred. Our research and development expenses consist primarily of:

salaries and related overhead expenses for personnel in research, development functions, and brood-stock husbandry;

fees paid to contract research organizations and consultants who perform research for us;

costs related to laboratory supplies used in our research and development efforts; and

costs related to ~~the operation of~~operating our field trials.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related costs for employees in executive, corporate, and finance functions. Other significant general and administrative expenses include corporate governance and public company costs, regulatory affairs, rent and utilities, insurance, and legal ~~service.~~services. We had thirteen and fifteen employees in our general and administrative group ~~at September 30, 2021.~~as of March 31, 2022 and 2021, respectively.

Other Income (Expense)

Interest expense includes the interest on our outstanding loans and the amortization of debt issuance costs. Other income (expense) includes bank charges, fees, interest income, miscellaneous gains or losses on asset disposals and realized gains or losses on investments.

Results of Operations

Comparison of the three months ended ~~September 30, 2021,~~March 31, 2022, to the three months ended ~~September 30, 2020~~March 31, 2021

The following table summarizes our results of operations for the three months ended ~~September 30,~~March 31, 2022 and 2021, ~~and 2020,~~ together with the changes in those items in dollars and as a percentage (all dollar amounts in thousands):


	Three Months Ended September 30,				Dollar	%	Three Months Ended March 31,				Dollar	%
	2021		2020		Change	Change	2022		2021		Change	Change
		(unaudited)						(unaudited)
Product revenue	$	455	$	68	387	569%	$	963	$	74	889	1,201%
Operating expenses:
Product costs		4,311		1,356	2,955	218%		3,276		1,555	1,721	111%
Sales and marketing		202		144	58	40%		248		319	(71)	(22)%
Research and development		580		458	122	27%		167		500	(333)	(67)%
General and administrative		2,177		1,723	454	26%		2,376		1,785	591	33%
Operating loss		6,815		3,613	3,202	89%		5,104		4,085	1,019	25%
Total other expense		50		37	13	35%		8		74	(66)	(89)%
Net loss	$	6,865	$	3,650	3,215	88%	$	5,112	$	4,159	953	23%

Product revenue for the three months ended ~~September 30, 2021~~March 31, 2022 consisted ~~of sales~~ of our GE Atlantic salmon and conventional Atlantic salmon ~~fry and eggs.~~fry. Product revenue for the three months ended ~~September 30, 2020~~March 31, 2021 consisted ~~of sales~~ of conventional Atlantic salmon fry and eggs. The increase in revenue is due to the harvesting and sale of our GE Atlantic salmon, which commenced in June 2021. We expect revenues for the remainder of ~~2021~~2022 to slowly grow as we increase our harvesting capability at our Indiana and Rollo Bay farm sites. ~~During the current period, we began harvesting and selling our GE Atlantic salmon from both our Indiana and Rollo Bay farms.~~

Since our production costs ~~also include a~~were higher than the net realizable value of the salmon produced, the current period includes an inventory value ~~adjustment~~charge of ~~$1.5~~$2.1 million based on the market price for salmon, our ~~current quarter~~ production yields and external processing and transportation costs. ~~Current~~For the corresponding period ~~costs were higher as a result of lower production yields for harvested GE salmon and higher transportation costs as compared to our expectations as of~~in 2021, the ~~end of the second quarter of 2021.~~inventory value charge was $1.5 million.

Sales and Marketing Expenses

Sales and marketing expenses for the three months ended ~~September 30, 2021,~~March 31, 2022, were updown from the corresponding period in ~~2020~~2021 due to decreases in donations, promotional expenses, and fees payable to outside consultants, offset by an increase in head count and ~~promotional expenses~~travel related to marketing activities for our salmon.

Research and Development Expenses

Research and development expenses for the three months ended ~~September 30, 2021,~~March 31, 2022, were updown from the corresponding period in ~~2020~~2021 due to ~~an increase~~a decrease in outside contract service fees and ~~personnel costs, offset~~field trials, and by an increase in broodstock cost transferred to production costs for related product revenue during the period. ~~During the current period, research activities included feed nutrition trials and discovery research in salmon immunology.~~

General and Administrative Expenses

General and administrative expenses for the three months ended ~~September 30, 2021,~~March 31, 2022, were up from the corresponding period in ~~2020~~2021 due to an increase in ~~outside consulting and advisory fees,~~recruitment, insurance costs, auditing fees, ~~insurance costs, personnel costs,~~stock compensation, and travel, offset by a decrease in legal ~~fees.~~fees, outside consulting and advisory fees, and personnel costs.

Total Other (Income) Expense

Total other (income) expense is comprised of interest on debt, bank charges, and interest income for the three months ended ~~September 30, 2021,~~March 31, 2022 and ~~interest on debt, bank charges, gain loss on equipment and interest income for the three months ended September 30, 2020.~~

~~Comparison of the nine months ended September 30, 2021, to the nine months ended September 30, 2020.~~

The following table summarizes our results of operations for the nine months ended September 30, 2021 and 2020, together with the changes in those items in dollars and as a percentage (all dollar amounts in thousands):

Nine Months Ended
September 30,
Dollar
%
2021
2020
Change
Change
(unaudited)
Product revenue
$
757
$
77
680
883%
Operating expenses:
Product costs
7,713
3,238
4,475
138%
Sales and marketing
1,069
332
737
222%
Research and development
1,512
1,663
(151)
(9)%
General and administrative
6,542
5,053
1,489
29%
Operating loss
16,079
10,209
5,870
57%
Total other expense
175
74
101
136%
Net loss
$
16,254
$
10,283
5,971
58%

~~Product Revenue~~

Product revenue for the nine months ended September 30, 2021 consisted of sales of our GE Atlantic salmon and conventional Atlantic salmon fry and eggs. Product revenue for the nine months ended September 30, 2020 consisted of sales of conventional Atlantic salmon fry and eggs. During the current nine month period, we began harvesting and selling our GE Atlantic salmon from both our Indiana and Rollo Bay farms. We expect revenues for the remainder of 2021 to slowly grow as we increase our harvesting capability at our Indiana and Rollo Bay farm sites.

~~Production Costs~~

Production costs for the nine months ended September 30, 2021, were up from the corresponding period in 2020, due to production cost increases related to the commencement of harvesting at the Indiana and Rollo Bay farms. Increases included headcount additions, feed costs and other direct supplies, as well as the costs for processing and transportation to bring our product to market. The current nine month period also includes a net realizable inventory value adjustment of $1.5 million based on our third quarter production yields and transportation costs. Costs were higher as a result of lower production yields for harvested GE salmon and higher transportation costs as compared to our expectations as of the end of the second quarter of 2021.

~~Sales and Marketing Expenses~~

Sales and marketing expenses for the nine months ended September 30, 2021, were up from the corresponding period in 2020 due to an increase in headcount, promotional expenses related to marketing activities for our salmon. Costs for the period also include a $514 thousand charge related to the donation program of conventional Atlantic salmon to local food charities.

~~Research and Development Expenses~~

Research and development expenses for the nine months ended September 30, 2021, were down from the corresponding period in 2020 due to an increase in broodstock cost transferred to production costs for related product revenue during the period, offset by increased outside contract service fees, field trials andpersonnel costs. During the current period, research activities included feed nutrition trials, discovery research in salmon immunology and work on a genome study to identify genes associated with economically important traits in salmon.

~~General and Administrative Expenses~~

General and administrative expenses for the nine months ended September 30, 2021, were up from the corresponding period in 2020 due to an increase in outside consulting and advisory fees, auditing fees, insurance costs, and personnel costs, offset by a decrease in legal fees, stock compensation charges and travel.

~~Total Other (Income) Expense~~

Total other (income) expense is comprised of interest on debt, bank charges, and interest income for the nine months ended September 30, 2021, and interest on debt, bank charges, gain loss on equipment and interest income for the nine months ended September 30, 2020.

Cash Flows

The following table sets forth the significant sources and uses of cash for the periods set forth below (in thousands):


	Nine Months Ended September 30,				Dollar	%	Three Months Ended March 31,				Dollar	%
	2021		2020		Change	Change	2022		2021		Change	Change
		(unaudited)
Net cash provided by (used in):
Operating activities	$	(15,111)	$	(10,585)	(4,526)	43%	$	(5,326)	$	(4,518)	(808)	18%
Investing activities		(83,819)		(1,545)	(82,274)	5,325%		(7,468)		(1,219)	(6,249)	513%
Financing activities		121,331		48,840	72,491	148%		(159)		120,865	(121,024)	(100)%
Effect of exchange rate changes on cash		27		(19)	46	(242)%		8		21	(13)	(62)%
Net increase in cash	$	22,428	$	36,691	(14,263)	(39)%
Net (decrease) increase in cash							$	(12,945)	$	115,149	(128,094)	(111)%

Net cash used in operating activities during the ~~nine~~three months ended ~~September 30, 2021~~March 31, 2022 was primarily comprised of our ~~$16.3~~$5.1 million net loss, offset by non-cash depreciation and stock compensation charges of ~~$1.6 million~~$702 thousand and increased by working capital uses of ~~$484~~$921 thousand. Net cash used in operating activities during the ~~nine~~three months ended ~~September 30, 2020~~March 31, 2021 was primarily comprised of our ~~$10.3~~$4.1 million net loss, offset by non-cash depreciation and stock compensation charges of ~~$1.5 million~~$552 thousand and increased by working capital uses of ~~$1.8 million.~~$911 thousand.

Spending on operations increased in the current period due to increases in production activities at our Rollo Bay and Indiana farm ~~sites and outside consulting and advisory fees.~~sites. Cash used by working capital increased in the current period and was ~~driven by increases~~due to an increase in inventory and prepaid expenses and ~~other current assets,~~a decrease in accounts payable and ~~receivables, offset by a reduction~~accrued liabilities, and accrued employee compensation.

During the three months ended March 31, 2022, we used $5.8 million for construction activities at our farm sites and the purchase of equipment, and $1.7 million on marketable securities purchases. During the same period in ~~inventory.~~2021, we used $1.2 million for construction charges and for equipment purchases, and $11 thousand on capitalized software.

~~Cash Flows from Investing Activities~~

During the nine months ended September 30, 2021, we used $4 million for renovations to our Indiana farm site, construction charges at our Rollo Bay farm site and renovations at our Fortune Bay hatchery, $196 thousand on deposits on equipment purchases and $79.6 million on marketable securities purchases. During the same period in 2020, we used $2.6 million for renovations to our Indiana farm site and for construction charges at our Rollo Bay site, offset by $100 thousand in proceeds from the sale of equipment and $1 million in net proceeds from a legal settlement.

We expect expenditures on capital projects to increase in future periods as we ~~commence~~continue construction of our Ohio farm. We currently estimate the construction costs to be in the range of $290 million to $320 million, including a reserve for potential contingencies of $30 million. We expect to finance this project cost through a combination of cash on hand and future issuances of debt. Estimating the cost and timing for the completion of this new and complex capital project is inherently difficult and subject to change based on a number of factors, including design changes, fluctuating costs of materials, labor shortages, the impact of the COVID-19 pandemic, construction delays, dependence on contractors, financing costs, customer requirements and unexpected complications. For more information, see “Our business plans include the need for substantial additional capital and without it we may not be able to implement our strategy as planned or at all” in our Annual Report on Form 10-K for the year ended December 31, 2021.

Cash Flows from Financing Activities

During the ~~nine~~three months ended ~~September 30,~~March 31, 2022, we made a $159 thousand debt repayment. During the same period in 2021, we received approximately $119.1 million in net proceeds from the issuance of ~~Common Shares~~shares of common stock in a public equity offering, ~~$1.7~~$1.6 million from the exercise of warrants, and ~~$606~~$187 thousand from new debt. This was offset by ~~$120~~$39 thousand in debt repayment. During the same period in 2020, we received approximately $44 million in net proceeds from the issuance of Common Shares in two public offerings, $524 thousand from the exercise of warrants, and $4.1 million from new debt. This was offset by $50 thousand in the repayment of debt.

Future Capital Requirements

~~In February 2021, we completed an equity raise with net proceeds of $119.1 million and we have $198~~We had $179.9 million of cash and cash equivalents, ~~and~~ marketable securities and restricted cash as of ~~September 30, 2021.~~March 31, 2022. While we have experienced net losses and negative cash flows from operations since inception, we believe that we have sufficient cash to meet our requirements for at least the next twelve months from the filing date. During the balance of 2022, we expect to use approximately $104 million of cash to fund our operations and construction costs for our Ohio farm.

In 2020, we entered into a term loan agreement with First Farmers Bank and Trust in the amount of $4 million, which is secured by the assets of our Indiana subsidiary and a corporate guarantee. The agreement contains certain financial and non-financial covenants, which if not met, could result in an event of default pursuant to the terms of the loan. At March 31, 2022, the Indiana subsidiary was in non-compliance with one of its loan covenants. Subsequent to period-end, First Farmers Bank and Trust revised the covenant and the Indiana subsidiary returned to compliance. The ability of the Indiana subsidiary to meet its debt covenants over the next twelve months is dependent upon its operating performance.

Until such time, if ever, as we can generate positive operating cash flows, we may finance our cash needs through a combination of equity offerings, debt financings, government or other third-party funding, strategic alliances, and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of holders of our common stock will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of our common stock. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through government or other third-party funding; marketing and distribution arrangements; or other collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or to grant licenses on terms that may not be favorable to us.

If we are unable to generate additional funds in the future through financings, sales of our products, government grants, loans, or from other sources or transactions, we will exhaust our resources and will be unable to maintain our currently planned operations. If we cannot continue as a going concern, our stockholders would likely lose most or all of their investment in us.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Critical Accounting Policies and Estimates

This Management’s Discussion and Analysis of Financial Condition and Results of Operations is based on our consolidated financial statements, which we have prepared in accordance with GAAP. The preparation of our consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.

Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021.

Emerging Growth Company and Smaller Reporting Company Status

We qualify as an emerging growth company (“EGC”), as defined in the JOBS Act. As an EGC, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies, including reduced disclosure about our executive compensation arrangements, exemption from the requirements to hold non-binding advisory votes on executive compensation and golden parachute payments and exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.

We may take advantage of these exemptions until December 31, 2022 or such earlier time that we are no longer an emerging growth company. We would cease to be an EGC earlier if we have more than $1.07 billion in annual revenue, we have more than $700.0 million in market value of our stock held by non-affiliates or we issue more than $1.0 billion of non-convertible debt securities over a three-year period. For so long as we remain an EGC, we are permitted, and intend, to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not EGCs. We may choose to take advantage of some, but not all, of the available exemptions.

In addition, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to “opt out” of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to “opt out” of such extended transition period or (ii) no longer qualify as an EGC. Therefore, the reported results of operations contained in our consolidated financial statements may not be directly comparable to those of other public companies.

We are also a “smaller reporting company,” meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million.

If we are a smaller reporting company at the time we cease to be an EGC, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to EGCs, smaller reporting companies have reduced disclosure obligations regarding executive compensation.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The following sections provide quantitative information on our exposure to interest rate risk and foreign currency exchange risk. We make use of sensitivity analyses, which are inherently limited in estimating actual losses in fair value that can occur from changes in market conditions.

Interest Rate Risk

Our primary exposure to market risk is interest rate risk associated with debt financing that we utilize from time to time to fund operations or specific projects. The interest on this debt is usually determined based on a fixed rate and is contractually set in advance. At ~~September 30, 2021,~~March 31, 2022, and December 31, ~~2020,~~2021, we had ~~$6.0~~$5.7 million and $5.8 million, respectively in interest-bearing debt instruments on our consolidated balance sheet. All of our interest-bearing debt is at fixed rates, except for our loan with First Farmers Bank and Trust, which has a rate reset in July 2025.

Foreign Currency Exchange Risk

Our functional currency is the U.S. Dollar. The functional currency of our Canadian subsidiary is the Canadian Dollar, and the functional currency of our U.S. and Brazil subsidiaries is the U.S. Dollar. For the Canadian Subsidiary, assets and liabilities are translated at the exchange rates in effect at the balance sheet date, equity accounts are translated at the historical exchange rate, and the income statement accounts are translated at the average rate for each period during the year. Net translation gains or losses are adjusted directly to a separate component of accumulated other comprehensive loss within shareholders’ equity.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We are not party to any legal proceedings the outcome of which, we believe, if determined adversely to us, would individually or in the aggregate have a material adverse effect on our future business, consolidated results of operations, cash flows, or financial position. We may, from time to time, be subject to legal proceedings and claims arising from the normal course of business activities.

Item 1A. Risk Factors

As disclosed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021, which was filed on March ~~9, 2021, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 and for the quarter ended June 30, 2021,~~10, 2022, there are a number of risk factors that could affect our business, financial condition, and results of operations. The following risk factors are either new or have changed materially from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2020 or our 10-Q for the quarter ended March 31, 2021 and for the 10-Q for the quarter ended June 30, 2021. You should carefully review the risks ~~described below and those~~ described in our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q, including our consolidated financial statements and related notes, and in other reports we file with the Securities and Exchange Commission, in evaluating our business. We cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition, or prospects. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment.

This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks faced by us described below, elsewhere in this Quarterly Report on Form 10-Q, in our Annual Report on Form 10-~~K, and in our Quarterly Report on 10-Q for the quarter ended March 31, 2021 and for the quarter ended June 30, 2021.~~K. See “Cautionary Note Regarding Forward-Looking Statements” for information relating to these forward-looking statements.

~~Risks Relating to our Business and Operations~~

~~We have a history of net losses and will likely incur future losses and may not achieve or maintain profitability.~~

In the period from incorporation to September 30, 2021, we have incurred cumulative net losses of approximately $165 million. These losses reflect our personnel, research and development, production and marketing costs. We have constructed a 250-metric-ton annual capacity production facility in Rollo Bay and in 2017 we acquired a facility in Indiana, which has undergone renovations to increase its annual capacity to 1,200 metric tons. We expect revenues to be modest for the remainder of 2021 as we increase our harvesting capability at our Indiana and Rollo Bay farms. However, our ability to realize revenues and the timing thereof are not certain, and achieving revenues does not assure that we will become profitable.

~~Our business plans include the need for substantial additional capital and we may not be able to implement our strategy as planned or at all.~~

Our strategy depends on our ability to develop and construct additional farms, including our planned Ohio farm. We have not yet begun construction of this farm and its construction, and others in the future, is contingent on a number of significant uncertainties, including those described below. As a result, we may be unable to construct such facilities as planned or at all. We may not be able to obtain the financing necessary to commence construction of our proposed facilities. We estimate that the construction cost for the Ohio farm will range between $290 million and $320 million, although this figure is likely to change as we finalize the design and proceed with construction. We do not have the financial resources required to commence the construction of the Ohio farm. We will seek to raise part of these necessary funds through debt financing. We may also need further funding if there are delays in construction or increased construction costs at our proposed construction site in Ohio. We may finance unanticipated construction costs by issuing equity securities or debt. The delay or failure of regulatory bodies to approve our construction plans, disruption and volatility in the financial markets, tighter credit markets and a downturn in the seafood market may negatively impact our ability to obtain financing. We may not have access to the required funding, or funding may not be available to us on acceptable terms.

While we are currently negotiating the terms of the acquisition of the site in Ohio for this farm, if we are unable to secure this location or others for future farms that satisfy our requirements, our business and results of operations would be materially and adversely impacted.

We may not be able to obtain the approvals and permits that will be necessary in order to construct our facilities as planned. We will need to obtain a number of required permits in connection with the hydrology, construction and operation of our farms, which is often a time-consuming process. If we experience delays in obtaining the required approvals and permits for our farms, our expected construction start date, commercial stocking and first sale of our GE salmon may be delayed. If we are unable to obtain the required approvals and permits for our farms, we will not be able to construct the farms. In addition, federal, state and local governmental requirements could substantially increase our costs, which could materially harm our results of operations and financial condition.

We have encountered cost increases in the expected construction cost of the Ohio farm, and may encounter further unanticipated difficulties and cost overruns in constructing this farm and other future farms. Preparing cost and timing estimates for complex RAS farms is inherently difficult and subject to change based on a number of factors, including site availability and characteristics, design changes, fluctuating costs of materials, labor shortages, the impact of the COVID-19 pandemic, construction delays, dependence on contractors, financing costs, customer requirements and other unexpected complications. As a result, we may encounter unanticipated difficulties and the construction and development of our proposed farms may be more costly or time-consuming than we anticipate.

Delays and defects may cause our costs to increase to a level that would make one or more of our farms too expensive to construct or unprofitable. We may suffer significant delays or cost overruns at our farms that could prevent us from commencing operations as expected as a result of various factors. These factors include shortages of workers or materials, construction and equipment cost escalation, transportation constraints, adverse weather, unforeseen difficulties or labor issues, or changes in political administrations at the federal, state or local levels that result in policy change towards genetically engineered foods in general or our products and farms in particular. Defects in materials or workmanship could also delay the commencement of operations of our planned farms, increase production costs or negatively affect the quality of our products. Due to these or other unforeseen factors, we may not be able to proceed with the construction or operation of our farms in a timely manner or at all.

~~Business, political, or economic disruptions or global health concerns, such as the COVID-19 pandemic, could seriously harm our current or planned business and increase our costs and expenses.~~

Broad-based business or economic disruptions, political instability, or global health concerns could adversely affect our current or planned production, sale, distribution, research and development, and expansion. For example, the COVID-19 pandemic has continued to spread, and the related adverse public health developments, including orders to shelter-in-place, travel restrictions, and mandated business closures, have adversely affected workforces, organizations, customers, economies, and financial markets globally, leading to an economic downturn and increased market volatility. It has also disrupted the normal operations of many businesses, including ours.

Global health concerns like the coronavirus pandemic could in themselves result in social, economic, and labor instability in the countries in which we or the third parties with whom we engage operate. The COVID-19 pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred, such as the shortage of packaging workers and transportation suppliers that we have experienced leading to slower and more expensive harvests; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, including salmon in the institutional sales chain that includes restaurants, has fallen, with a resulting drop in the prices for those goods and services. We have been impacted by the reduction in food service demand for salmon due to the pandemic in the form of significantly lower than expected sales and a reduction in the value of our inventory. In response to the COVID-19 pandemic, we have provided our administrative employees with the option to work remotely, and we have limited the number of staff in any given area of our farm sites. We have also implemented policies and procedures at our farms to react to any outbreak of the virus.

As a result of the COVID-19 pandemic, we have and may continue to experience disruptions that could severely impact our business, including disruptions or restrictions on our ability to travel, obtain regulatory approvals from the FDA and other regulators, pursue partnerships and other business transactions, conduct production activities, and make shipments, as well as be impacted by the temporary closure of the facilities of suppliers. While we have taken steps to address the impact of the coronavirus on our operations, we and our service providers have experienced labor and transportation shortages that have slowed the pace and increased the expense of commercial harvests of our products. In addition, labor shortages are creating additional challenges to our efforts to meet the annual harvest expectations at our existing facilities, which has necessitated increased culling to rebalance the biomass of our fish and lower our stocking densities. Though we believe this action will position us to achieve an annual harvest volume of 1,200 metric tons at the farm, we do not expect to reach this level during the next twelve months.

We also cannot presently predict the scope and severity of any additional business shutdowns or disruptions or the future impact on consumer demand. For example, we have been primarily impacted by a reduction in the market price and demand for Atlantic salmon due to the pandemic’s impact on the food service sector. This had and continues to have a negative impact on our revenue and inventory value. If we or any of the third parties with whom we engage, including suppliers, distributors, service providers, regulators,

and overseas business partners, experience additional or continued shutdowns or other disruptions, or consumer demand remains materially reduced, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted, our anticipated revenues could decrease, and our costs and expenses could continue to rise as a result of our efforts to address such disruptions.

In addition, the trading prices for our common stock and the stock of other biotechnology and food companies have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. The COVID-19 pandemic continues to rapidly evolve, and the extent to which it may impact our business and planned programs will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease; the duration of the pandemic; travel restrictions and other actions to contain the pandemic or address its impact, such as social distancing and quarantines or lock-downs in the United States, Canada, and other countries; business closures or business disruptions; and the effectiveness of actions taken in the United States, Canada, and other countries to contain and address the disease.

~~Ethical, legal, and social concerns about genetically engineered products could limit or prevent the use of our products and limit our revenues.~~

Our technologies include the use of genetic engineering. Public perception about the safety and environmental hazards of, and ethical concerns over, genetically engineered products could influence public acceptance of our technologies and products. Activist groups opposing the genetic engineering of organisms have in the past pressured a number of retail food outlets and grocery chains to publicly state that they will not carry genetically engineered Atlantic salmon, and they could file lawsuits to prevent the production and sale of our products. If we are not able to overcome the ethical, legal, and social concerns relating to genetic engineering, products using our technologies may not be accepted in the marketplace, and demand for our products could fall short of what we expect. These concerns could also result in increased expenses, regulatory scrutiny, delays, or other impediments to implementation of our business plan. For example, in January 2021 the House of Representatives introduced the Prevention of Escapement of Genetically Altered Salmon in the United States Act (“HR 273”), which would prohibit our business unless we obtain permits from the Under Secretary of Commerce for Oceans and Atmosphere, in consultation with the Director of the United States Fish and Wildlife Service and other agencies.

The subject of genetically engineered products has received negative publicity, which has aroused public debate. This adverse publicity could lead to lawsuits against the production, distribution, and sale of genetically engineered products; greater regulation of those products; and trade restrictions on their importation. Further, there is a concern that products produced using our technologies could be perceived to cause adverse events, which could also lead to negative publicity.

~~We may incur significant costs complying with environmental, health, and safety laws and regulations, and failure to comply with these laws and regulations could expose us to significant liabilities.~~

Our operations are subject to a variety of federal, state, local, and international laws and regulations governing, among other matters, the use, generation, manufacture, transportation, international shipment, storage, handling, disposal of, and human exposure to our products in both the United States and overseas, including regulation by governmental regulatory agencies, such as the FDA and the U.S. Environmental Protection Agency. We have incurred, and will continue to incur, capital and operating expenditures and other costs in the ordinary course of our business in complying with these laws and regulations. Additional laws and regulations, such as HR 273, could be adopted in the future further regulating our business.

~~We may become subject to increasing regulation, changes in existing regulations, and review of existing regulatory decisions.~~

Regulations pertaining to genetically engineered animals are still developing and could change from their present state. In addition, new legislation could require new regulatory frameworks, changes in existing regulation, or re-evaluation of prior regulatory decisions. For example, despite the FDA’s final determination that AquAdvantage salmon may be sold without being labeled as a genetically engineered product, a provision added to the 2016 Omnibus Appropriations Act required the FDA to issue final guidance for such labeling. The FDA was therefore obligated to maintain an Import Alert starting in January 2016 that prohibited import of AquAdvantage salmon until such guidance was finalized or the provision was no longer effective. On March 8, 2019, several months after the USDA promulgated its final rule establishing the Disclosure Standard, which included disclosure requirements for bioengineered foods, including AquAdvantage salmon, the FDA lifted the Import Alert.

Similarly, in July 2017, a bill was introduced in the United States Senate that could have, had it become law, required labeling unique to, as well as re-examination of the environmental assessments used by the FDA in its 2015 approval of the NADA for, AquAdvantage salmon. While this bill was reintroduced in January 2019 without the requirement for re-examination of those environmental assessments, any such legislatively imposed review of a completed regulatory process could result in new restrictions on, or delays in, commercialization of our product in the United States. We could be subject to increasing or more onerous regulatory hurdles as we attempt to commercialize our product, which could require us to incur significant additional capital and operating expenditures and

other costs in complying with these laws and regulations. Our regulatory burdens could also increase if AquAdvantage salmon are found, or believed, to grow to a larger final size than conventional Atlantic salmon.

In addition, the 2020 Appropriations Act, which was signed into law in December 2019, contained an amendment that requires that any bioengineered animal approved by FDA prior to the effective date of the Disclosure Standard shall include the words ‘‘genetically engineered’’ prior to the existing acceptable market name. While the Company believes that this labeling requirement is unnecessary and redundant to the requirement of the Disclosure Standard, it will comply with all applicable laws.

Further, in January 2021, the U.S. House of Representatives introduced HR 273, which would place significant restrictions and regulatory requirements on our business. This act is currently under review by the House of Representatives’ natural resources committee.

~~Additional regulatory and lawmaking activity within the United States and abroad could increase our costs and/or delay or prevent the production and sales of our AquAdvantage salmon.~~

~~We may be required to write-down the value of our inventory if its net realizable value is less than its accumulated cost at the end of a reporting period.~~

Our fish-in-process inventory is a biological asset and is stated on our balance sheet at the lower of cost or net realizable value, where net realizable value is calculated as the estimated market price less the estimated costs of processing, packaging and transportation. Any adjustments to the carrying value of inventory are reported as a component of production costs on our income statement. Such adjustments may be material in any given period and could adversely affect our financial condition and results of operations. Until such time as our net realizable value is consistently in excess of inventory costs, our inventory may be subject to significant market value risk. During the third quarter of 2021, we recognized a $1.5 million charge to reduce the value of our inventory to its net realizable value, based on our current quarter production yields and transportation costs which were higher than our expectations as of the end of the second quarter of 2021.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

~~Letter Agreement with Third Security~~

On July 30, 2021, we entered into a letter agreement (the “Letter Agreement”) with TS Aquaculture LLC (“TS Aquaculture”) and certain of its affiliates that required that we file a registration statement to register the shares of Common Stock held by TS Aquaculture and certain of its affiliates and keep it effective for a period of not less than 24 months. The registration statement was filed on August 5, 2021. TS Aquaculture agreed to pay all expenses incurred in connection with such registration statements. We and TS Aquaculture also agreed to modify the terms of the relationship agreement between us and TS Aquaculture as successor in interest to Intrexon Corporation (the “Relationship Agreement”) so as to restrict assignments of the rights of TS Aquaculture thereunder.None

The entry into the Letter Agreement constituted a “related party transaction” as defined by Item 404 of Regulation S-K because TS Aquaculture is an affiliate and has appointed three members of our board pursuant to the Relationship Agreement. Because of this, the Letter Agreement was approved by the disinterested directors and the Audit Committee was responsible for reviewing, negotiating and approving the terms of the Letter Agreement. Additionally, the Company has a policy that the Audit Committee is responsible for the review and approval of any “related party transaction”, as such term is defined in Item 404 of Regulation S-K, after it has reviewed and considered all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm’s length transaction and the extent of the related party’s interest in the transaction.

~~This transaction was approved by the disinterested members of the Board on July 27, 2021, upon the recommendation of the Audit Committee.~~
‎


	September 30, 2021		December 31, 2020
Feed	$	224,941		244,311
Eggs and fry		59,003		54,929
Packaging		—		6,452
Fish in process, net		938,279		1,219,685
Inventory, net	$	1,222,223		1,525,377


	March 31, 2022		December 31, 2021
Feed, net	$	306,635		162,047
Eggs and fry		97,939		—
Fish in process		1,209,012		926,360
Finished goods		62,096		171,503
Inventory, net	$	1,675,682		1,259,910


	September 30, 2021		December 31, 2020		March 31, 2022		December 31, 2021
Land	$	725,536	$	724,785	$	730,345	$	725,799
Building and improvements		15,500,661		14,048,917		15,712,641		15,580,385
Construction in process		4,467,496		3,212,287		12,286,984		8,119,575
Equipment		15,432,906		13,819,210		16,220,935		15,981,408
Office furniture and equipment		240,872		202,596		242,102		240,939
Vehicles		36,247		28,700		36,837		36,280
Total property and equipment	$	36,403,718	$	32,036,495	$	45,229,844	$	40,684,386
Less accumulated depreciation and amortization		(6,394,781)		(5,106,157)		(7,401,679)		(6,869,267)
Property, plant and equipment, net	$	30,008,937	$	26,930,338	$	37,828,165	$	33,815,119


	Shares	Weighted ‎average grant ‎date fair value		Shares	Weighted ‎average grant ‎date fair value
Balance at December 31, 2020	72,653	$	1.90
Unvested at December 31, 2021				65,100	$	4.10
Granted	43,837		6.67	240,777		1.52
Vested	(48,858)		3.20	(121,232)		2.14
Balance at September 30, 2021	67,632	$	4.05
Forfeited				—		—
Unvested at March 31, 2022				184,645	$	2.03


Exhibit Number		Exhibit Description
~~10.1~~		Letter Agreement between the Registrant and Third Security and its affiliates dated July 30, 2021 (previously filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 4, 2021, and incorporated herein by reference).
31.1		Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1+		Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL instance document.
101.SCH		XBRL taxonomy extension schema document.
101.CAL		XBRL taxonomy extension calculation linkbase document.
101.LAB		XBRL taxonomy label linkbase document.
101.PRE		XBRL taxonomy extension presentation linkbase document.
101.DEF		XBRL taxonomy extension definition linkbase document.
104		Cover Page Interactive Data File-the cover page interactive data file does not appear in the Interactive Data File because the XBRL tags are embedded within the Inline XBRL document.


	September 30, 2021		December 31, 2020
Accounts payable	$	860,673	$	799,888
Accrued payroll including vacation		577,534		583,301
Accrued professional fees and contract services		394,433		278,165
Accrued taxes and other		121,076		98,749
Accounts payable and accrued liabilities	$	1,953,716	$	1,760,103


				September 30, 2021		December 31, 2020
	Lease	Lease	Remaining	Remaining	Lease	Remaining	Lease
	Type	Term	Years	Payments	Liability	Payments	Liability

Maynard Office Lease	Operating	Mar 2023	1.4	101,403	92,114	150,918	134,099
Indiana Auto Lease	Operating	Feb 2021		-	-	1,157	821
Indiana Well Lease	Operating	Dec 2048	27.2	674,810	214,060	686,809	217,890
Total				776,213	306,174	838,884	352,810
Less: current portion				(83,960)	(65,072)	(83,571)	(62,483)
Long-term leases				$ 692,253	$ 241,102	$ 755,313	$ 290,327


	Number of ‎options	Weighted ‎average ‎exercise price
Outstanding at December 31, 2020	948,855	$	3.25
Issued	—		-
Exercised	(530,414)		3.25
Expired	—		-
Outstanding at September 30, 2021	418,441		3.25
Exercisable at September 30, 2021	418,441		3.25


		AQUABOUNTY TECHNOLOGIES, INC.

~~November 4, 2021~~May 5, 2022		/s/ Sylvia Wulf
		Sylvia Wulf
		President, Chief Executive Officer, and Director (Principal Executive Officer)

~~November 4, 2021~~May 5, 2022		/s/ David A. Frank
		David A. Frank
		Chief Financial Officer and Treasurer (Principal Financial Officer and Principal Accounting Officer)